Allakos Inc(NASDAQ:ALLK) 
Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic es...
Website: http://www.allakos.com
Founded: 2012
Full Time Employees: 114
CEO: Robert D. Alexander Ph.D.
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2024-11-13
P
O 1.30
H 1.30
L 1.25
C 1.30
V 509,976
10EMA 1.30
20EMA 1.30
60EMA 1.30
120EMA 1.30
250EMA 1.30